EMPA-KIDNEY

Study of Heart and Kidney Protection with Empagliflozin

Paziente / Popolazione Intervento / Esposizione Confronto Esito

In 6,609 patients across a broad spectrum of CKD, empagliflozin reduced kidney-disease progression or cardiovascular death compared with placebo.

6609

Disegno

Double-blind RCT, stopped early

Esito

CKD progression or cardiovascular death

Rilevanza

Risultato13.1% vs 16.9%; HR 0.72 (95% CI 0.64–0.82; p<0.001)

The EMPA-KIDNEY Collaborative Group. N Engl J Med. 2023;388(2):117-127. 10.1056/NEJMoa2204233

Discussione e critica

Widest CKD eligibility yet (eGFR down to 20); no significant benefit in the UACR <30 mg/g subgroup.